Phase 2 Results shows the potential of Vergent Biosciences' Cancer-Specific Fluorescent Imaging Compound to Improve Success of Lung Cancer Surgeries

Vergent Bioscience, a company working in the clinical-stage biotechnology industry creating cancer-specific diagnostic tools, along with its fully controlled Australian branch Vergent Bioscience Australia Pty Ltd, have shared novel findings at the IASLC 2023 World Conference on Lung Cancer. These findings strongly imply that their tumor-targeted fluorescent imaging agent shows activity and can safely be used to detect tumor tissue in the lung.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Results from the Phase 2 clinical trial examining VGT-309 indicate that the trial drug could enhance surgeons' capacity to locate hard-to-spot and previously missed tumors in real-time, thereby potentially benefitting patient outcomes.

"The prevalent uptake of minimally invasive surgeries for lung cancer, in addition to the increasing discovery of small tumors, has made it increasingly difficult for surgeons to locate all tumor cells during procedures," stated Gavin M. Wright, PhD, associate professor and director of Surgical Oncology at St. Vincent's Hospital in Melbourne, Australia. "The results from our research validate that VGT-309 could augment the effectiveness of minimally invasive procedures by improving the visibility of tumors and reducing the likelihood of residual cancer cells." 

The Phase 2 trial assessed the safety and effectiveness of VGT-309 in 27 patients suspected or confirmed of having lung cancer and were suitable candidates for surgery. Every individual involved in the study was given a VGT-309 infusion either on the day preceding the surgery or on the day of the procedure itself. After an initial attempt to locate each tumor using conventional surgical methods, the scientists employed a commercially available NIR endoscope to examine the lung for any leftover tumor tissue, the presence of which was then verified pathologically.

The study results shared at the WCLC23 offer persuasive proof that VGT-309 possesses a strong affinity for malignant tissue in the lung, thereby enhancing the chances of surgeons identifying all tumor tissue during the operation. Of the 27 participants, 23 were affirmed to have cancer, one had a typical carcinoid, and three had non-neoplastic conditions.

The tumor types visualized during surgery with VGT-309 and NIR imaging included: non-small cell lung cancer, metastatic carcinoma of breast origin, and high-grade epithelioid sarcoma. In two patients, VGT-309 detected tumor tissue in the lymph nodes that were pathologically confirmed as cancerous, leading to upstaging that could potentially influence patient treatment and outcomes.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 15, 2023, there are 2723 investigational drugs for the Lung Cancer, including 915 applicable targets,1914 R&D institutions involved, with related clinical trials reaching 17116，and as many as 222835 patents.

VGT-309 is a tumor-targeted imaging agent designed to enable a complete product solution for optimal tumor visualization during open, MIS, and robotic-assisted surgical procedures. This approach provides distinct clinical advantages and positions VGT-309 as an ideal tumor-imaging agent. VGT-309 is specifically indicated for lung cancer and breast cancer. As it progresses through Phase 2 clinical trials, further research will determine its effectiveness and potential impact on patient care.